MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer

Tang, Sheng; Li, Shuangjiang; Liu, Tao; He, Yiwei; Hu, Haiyang; Zhu, Ying–Hui; Tang, Shoujun; Zhou, Haining

doi:10.1016/j.canlet.2020.12.040

Cited by 40 publications

(21 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As non-coding RNAs, miRNAs can form a complex regulatory network and play an important role in the occurrence and development of various malignant tumors (26). In addition, due to their tissue-specific and highly conserved characteristics, the abnormal expression of miRNAs may be used as an important marker for evaluating cancer progression and patient prognosis, including in SGC (9,10,27,28).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miRNAs/miRs) play an important role in various types of carcinoma, including sebaceous gland carcinoma (SGC) of the eyelid. miR-3907 was found to be highly expressed in lung cancer; however, to the best of our knowledge, the biological role of miR-3907 in SGC has not previously been evaluated. The aim of the present study was to determine the role and mechanism of miR-3907 in the occurrence and development of SGC. miR-3907 was screened and identified as a novel upregulated miRNA in SGC tissues and cells, as determined using miRNA microarrays and reverse transcription-quantitative (RT-q) PCR analyses. Compared with the control group, cellular proliferation and migration were enhanced in the miR-3907 mimics group, and decreased in the miR-3907 inhibitor group. Moreover, miR-3907 negatively regulated thrombospondin 1 (THBS1) expression, as shown by bioinformatics prediction, RT-qPCR, western blotting and dual-luciferase reporter assays. In addition, compared with the control group, the small interfering (si) siRNA-THBS1 group exhibited enhanced proliferation and migration abilities, which were decreased in the THBS1 overexpression group. Furthermore, THBS1 overexpression was found to attenuate the stimulative effect of miR-3907 mimics, and THBS1-knockdown reversed the inhibitory effect of the miR-3907 inhibitor in SGC cells. Collectively, the results of the present study indicated that miR-3907 promoted the proliferation and migration of SGC by downregulating THBS1, and that this axis may be a potential target for the prognostic assessment and treatment of SGC.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Many clinical trials performed on advanced NSCLC patients at baseline are based on analyses made with cf-DNA. However, other blood components of patients such as CTCs, extracellular vesicles (EVs), including exosomes, platelets and microRNAs are of interest [ 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 ] ( Figure 4 ). The integration of analyses of different components may optimize in the near future the global biological information necessary to make better strategic therapeutic decisions [ 137 , 143 ].…”

Section: Ngs With Blood At Diagnosis Of Advanced Non-small Cell Lung Carcinoma: How To Optimize?mentioning

confidence: 99%

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

Hofman

2021

Cancers

View full text Add to dashboard Cite

Recently, the liquid biopsy (LB), a non-invasive and easy to repeat approach, has started to compete with the tissue biopsy (TB) for detection of targets for administration of therapeutic strategies for patients with advanced stages of lung cancer at tumor progression. A LB at diagnosis of late stage non-small cell lung carcinoma (NSCLC) is also being performed. It may be asked if a LB can be complementary (according to the clinical presentation or systematics) or even an alternative to a TB for treatment-naïve advanced NSCLC patients. Nucleic acid analysis with a TB by next-generation sequencing (NGS) is gradually replacing targeted sequencing methods for assessment of genomic alterations in lung cancer patients with tumor progression, but also at baseline. However, LB is still not often used in daily practice for NGS. This review addresses different aspects relating to the use of LB for NGS at diagnosis in advanced NSCLC, including its advantages and limitations.

show abstract

“…miRNA is functionally silencing RNA and suppresses post transcription of gene regulation [ 29 ]. Circulating miRNAs are released into the blood and have the potential as biomarkers in various diseases [ 30 , 31 , 32 ]. An increased miR-18a-5p in the skin is observed in patients with TEN [ 33 ].…”

Section: Clinical Sign and Biomarker For Drug Eruptionmentioning

confidence: 99%

Diagnostic Tools and Biomarkers for Severe Drug Eruptions

Yoshioka

Sawada

Nakamura

2021

IJMS

View full text Add to dashboard Cite

In accordance with the development of human technology, various medications have been speedily developed in the current decade. While they have beneficial impact on various diseases, these medications accidentally cause adverse reactions, especially drug eruption. This delayed hypersensitivity reaction in the skin sometimes causes a life-threatening adverse reaction, namely Stevens-Johnson syndrome and toxic epidermal necrolysis. Therefore, how to identify these clinical courses in early time points is a critical issue. To improve this problem, various biomarkers have been found for these severe cutaneous adverse reactions through recent research. Granulysin, Fas ligands, perforin, and granzyme B are recognized as useful biomarkers to evaluate the early onset of Stevens-Johnson syndrome and toxic epidermal necrolysis, and other biomarkers, such as miRNAs, high mobility group box 1 protein (HMGB1), and S100A2, which are also helpful to identify the severe cutaneous adverse reactions. Because these tools have been currently well developed, updates of the knowledge in this field are necessary for clinicians. In this review, we focused on the detailed biomarkers and diagnostic tools for drug eruption and we also discussed the actual usefulness of these biomarkers in the clinical aspects based on the pathogenesis of drug eruption.

show abstract

MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer

Cited by 40 publications

References 189 publications

MicroRNA‑3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1

MicroRNA‑3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

Diagnostic Tools and Biomarkers for Severe Drug Eruptions

Contact Info

Product

Resources

About